Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe infections caused by susceptible bacteria in hospitalized patients.

GNH USA supplies Meropenem Qilu as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections.

- Complicated intra‑abdominal infection: provides broad‑spectrum coverage against Gram‑negative and anaerobic organisms. - Complicated urinary tract infection: eradicates susceptible uropathogens, including resistant strains. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves bacterial clearance in severe lung infections.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Elevated liver enzymes - Headache - Injection site pain

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment - Anaphylactic or severe hypersensitivity reactions - Clostridioides difficile‑associated colitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Acute renal failure

Meropenem should be used with caution in specific clinical situations.

- Renal impairment: dose adjustment may be required. - History of seizures: monitor neurologic status closely. - Allergy to β‑lactam antibiotics: avoid use. - Concurrent valproic acid therapy: monitor for reduced valproate levels. - Use with other nephrotoxic drugs: increase risk of renal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Valproic acid: reduces valproate concentrations, increasing seizure risk. - Probenecid: may raise meropenem plasma levels, heightening toxicity. - Concurrent nephrotoxic agents: amplify renal damage.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance of meropenem. - Aminoglycosides: additive nephrotoxic potential. - Warfarin: monitor INR as carbapenems can alter anticoagulant effect.